Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
$0.00
$0.00
$0.00
$0.05
N/A-2.8212,599 shs1,350 shs
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$1.28
$1.06
$0.81
$1.76
$30.27M0.79132,069 shs133,511 shs
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$1.58
-7.6%
$1.41
$0.95
$5.99
$17.87M1.4383,365 shs130,492 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
$2.14
$7.94M0.688.94 million shsN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$0.82
+16.5%
$0.82
$0.66
$2.29
$31.96M1.57164,241 shs816,556 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00%0.00%-95.00%-83.33%-99.00%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
0.00%+5.79%+41.44%+43.58%-13.51%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-7.60%+0.64%-1.25%+35.04%-69.79%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%0.00%0.00%0.00%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
+16.50%+15.71%+1.42%-10.61%-62.77%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
2.868 of 5 stars
3.73.00.00.03.30.80.6
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
4.5277 of 5 stars
3.85.00.03.92.70.80.6
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
1.0793 of 5 stars
0.03.00.00.03.80.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00
N/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
3.33
Buy$10.00681.25% Upside
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
3.50
Strong Buy$13.17733.33% Upside
ObsEva SA stock logo
OBSV
ObsEva
0.00
N/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CALA, OBSV, SCYX, MRKR, and ENLV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/21/2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/A$1.00 per shareN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$6.59M2.71N/AN/A$1.73 per share0.91
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/A$0.41 per shareN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$2.63M12.15N/AN/A$1.45 per share0.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
-$39.65MN/A0.00N/AN/AN/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$15.01M-$0.66N/AN/AN/AN/A-57.67%-50.52%8/29/2025 (Estimated)
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$10.73M-$1.33N/AN/AN/A-224.46%-101.87%-83.02%8/13/2025 (Estimated)
ObsEva SA stock logo
OBSV
ObsEva
-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$21.29M-$0.56N/A16.38N/A-1,030.04%-53.47%-32.86%8/6/2025 (Estimated)

Latest CALA, OBSV, SCYX, MRKR, and ENLV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/30/2025Q1 2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$0.16-$0.15+$0.01-$0.15N/AN/A
5/15/2025Q1 2025
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.23-$0.17+$0.06-$0.11$0.14 million$0.26 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/A
7.20
7.20
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/A
6.79
6.79
ObsEva SA stock logo
OBSV
ObsEva
N/A
0.61
0.61
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/A
5.83
5.83

Institutional Ownership

CompanyInstitutional Ownership
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
1.02%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
22.39%
ObsEva SA stock logo
OBSV
ObsEva
17.52%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
54.37%

Insider Ownership

CompanyInsider Ownership
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
6.60%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
12.28%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
14.50%
ObsEva SA stock logo
OBSV
ObsEva
14.40%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
4.86%
CompanyEmployeesShares OutstandingFree FloatOptionable
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
604.87 million4.55 millionNot Optionable
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
7023.65 million20.75 millionOptionable
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
6011.31 million9.67 millionNot Optionable
ObsEva SA stock logo
OBSV
ObsEva
5077.97 million66.74 millionNot Optionable
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
6039.02 million37.12 millionOptionable

Recent News About These Companies

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
Scynexis to present preclinical data on SCY-247 at ESCMID Meeting
SCYNEXIS Full Year 2024 Earnings: Misses Expectations
Maxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)
Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Calithera Biosciences stock logo

Calithera Biosciences NASDAQ:CALA

$0.0001 0.00 (0.00%)
As of 07/14/2025 02:30 PM Eastern

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Enlivex Therapeutics stock logo

Enlivex Therapeutics NASDAQ:ENLV

$1.28 0.00 (0.00%)
Closing price 07/14/2025 04:00 PM Eastern
Extended Trading
$1.25 -0.03 (-1.95%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Marker Therapeutics stock logo

Marker Therapeutics NASDAQ:MRKR

$1.58 -0.13 (-7.60%)
Closing price 07/14/2025 04:00 PM Eastern
Extended Trading
$1.57 -0.01 (-0.38%)
As of 08:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

ObsEva stock logo

ObsEva NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

SCYNEXIS stock logo

SCYNEXIS NASDAQ:SCYX

$0.82 +0.12 (+16.50%)
Closing price 07/14/2025 04:00 PM Eastern
Extended Trading
$0.77 -0.05 (-5.98%)
As of 08:45 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.